SCINTOMICS is a leading provider of innovative tracer technologies in the field of molecular imaging and radioligand therapy in oncology. We are committed to targeted diagnostics and therapeutics, so called THERANOSTICS, and corresponding radiopharmaceutical technologies. Our strong focus towards personalized cancer care is reflected by an exceptional portfolio of innovative tracer technologies and the clinical development of Theranostic through subsidiaries, joint ventures, alliances and licenses.
Proven track records
SCINTOMICS was founded in 2006 with the aim of developing widely applicable and easy-to-use synthesis modules for radiopharmaceuticals, and providing this powerful instrumentation to nuclear medicine clinics and research facilities for the fully automated production of radiopharmaceuticals all around the world. By installation of hundreds of Synthesis Modules to Customers all over the world, we succeeded in building up a strong medical and scientific network, while always adhering to our principle: Promising the possible, building and strengthening the reputation through trust.
As one of the leading suppliers of automated synthesizers for theranostics, we recognized very early an innovation gap which hindered or even prevented the conversion of promising new radiopharmaceuticals into clinical development.
Learn more about how Radio-Theranostics can improve cancer treatment
Rich and unique portfolio
In 2010 SCINTOMICS expanded the scope of its activities and started to promote targeted radiopharmaceuticals in the oncological field, such as PSMA I&T, HA-DOTATATE, Avebetrin, Pentixafor and other radiopharmaceuticals by offering dedicated solutions for in-house production of such tracers. SCINTOMICS further expanded by building up a substantial portfolio of proprietary radiopharmaceuticals, such as rhPSMA, siPSMA, PSMA PNT2002 and rhTATE to mention only a few.
Scintomics Mission
Bridging preclinical research and clinical development to accelerate the clinical implementation of unique cancer diagnostics and therapeutics for the long term benefit of cancer patients.
ATT
Scintomics Molecular – Applied Theranostics Technologies
As a growing player in the radiopharmaceutical business, a subsidiary of SCINTOMICS, Scintomics Molecular – Applied Theranostics Technologies (ATT) was founded in 2018. It continues, in an independent manner, the Automation & Precursor business segment, that is the sale of proprietary and non-proprietary labeling precursors and the distribution of corresponding fully automated synthesizers and consumables.
Visit website
PARTNER
Blue Earth Diagnostics
Blue Earth Diagnostics, an indirect subsidiary of Bracco Imaging S.p.A., is a growing international molecular imaging company focused on delivering innovative, well-differentiated diagnostic solutions that inform patient care. Formed in 2014, the Company’s success is driven by its management expertise and supported by a demonstrated track record of rapid development and commercialization of positron emission tomography (PET) radiopharmaceuticals. Blue Earth Diagnostics’ expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology. Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.
Visit website
PARTNER
POINT
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT is transforming precision medicine by combining a portfolio of best-in-class radio-pharmaceutical assets, a seasoned management team, an industry-leading pipeline, in-house manufacturing capabilities, and secured supply for rare medical isotopes like Actinium-225 and Lutetium-177.
Visit website
PARTNER
BayPAT
Bayerische Patentallianz GmbH (BayPAT) is the central patent and marketing agency to foster technology transfer of Universities, University Hospitals and Universities of Applied Sciences in Bavaria since 2007. With many years of experience and excellence in patenting and licensing of new technologies, BayPAT commercializes innovations from 33 research institutes. Connecting science and economy, BayPAT strives to make the valuable inventions from its clients commercially exploitable by industry.
Visit websiteOur milestones
Below you can find an overview of our milestones since the foundation of Scintomics.
2023
Posluma Market Approval
U.S. FDA Approves Blue Earth Diagnostics’ POSLUMA® (Flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET Imaging Agent for Prostate Cancer
2021
Blue Earth Diagnostics
Licensing agreement with Blue Earth Diagnostics for therapeutic rhPSMAs.
2021
Aquistion of PentixaPharm by Eckert & Ziegler
Acquisition of the majority of PentixaPharm by Eckert & Ziegler Strahlen- und Medizintechnik AG
2020
SCINTOMICS Molecular, Applied Theranostics Technologies GmbH (att)
Scintomics conducted a reorganization to focus on the clinical development of the company’s projects. Subsidiary Scintomics ATT takes over module, consumable and precursor business.
2019
Point Biopharma
Licensing agreement with POINT Biopharma for therapeutic PSMA (world - except Asia).
2019
Foundation of PentixaPharm
A joint Venture of SCINTOMICS and 1717LSV on CXCR4 ligands
2019
TUM Award
Scintomics receives TUM Presidential Entrepreneurship Award.
2018
Foundation
Foundation of Scintomics ATT as subsidiary of Scintomics
2018
Blue Earth Diagnostics
Licensing agreement with BlueEarth Diagnostics for diagnostic rhPSMA.
2017
Next Generation CXCR4 compounds
Licensing of CXCR4 follow-up technology from TUM / BayPAT.
2017
rhPSMA technology
Licensing of rhPSMA technology from TUM / BayPAT.
2015
Pentixther for therapy
The CXCR4 therapeutic tracer Pentixather is bought from TUM / BayPAT.
2015
IMAZA for ACC
IMAZA (Theridat) as a promising theranostic tool for adrenocortical tumors is licensed from UKW / BayPAT.
2013
18F-Labeling Technology
18F-Labeling by direct elution without time consuming azeotropic drying is now possible with licensed IP from TUM/BayPat.
2013
Acquistion of radiolabeled RGD peptides
TRAP(RGD)3 (Avebetrin) technology is bought from TUM / BayPAT
2013
Pentixafor is born
Scintomics buys the IP of CXCR4 imaging compounds (Pentixafor) from TUM / BayPAT
2010
Growth
Installation of >150 production systems worldwide.
2010
Introduction of GMP compliant GRP MODULES
Start of GRP Module Series.
2006
Foundation
Foundation of Scintomics GmbH by Prof. H.J. Wester.